2. Search Result
Search Result
Results for "

EGFR-IN-3

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

1

Peptides

2

Inhibitory Antibodies

1

Natural
Products

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12000
    AG490
    Maximum Cited Publications
    165 Publications Verification

    TyrphostIN AG490; TyrphostIN B42

    		 EGFR STAT JAK Autophagy Cancer
    AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.
    AG490
  • HY-P99676
    Izalontamab

    SI-B001; BL-B01D1 Antibody

    		 EGFR Cancer
    Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .
    Izalontamab
  • HY-13984
    NT-1
    1 Publications Verification

    EGFR mutant-IN-3

    		 EGFR ERK Apoptosis Drug Derivative Cancer
    NT-1 (EGFR mutant-IN-3) is a potent mutant EGFR inhibitor and an analog of Osimertinib (HY-15772). This mutant EGFR inhibitor suppresses FGFR WT with an IC50 of 0.4 nM. NT-1 also inhibits EGFR L858R, EGFR Exon 19 deletion and EGFR T790M. NT-1 exerts deeper inhibition on p-EGFR and p-ERK, and induces tumor cell apoptosis. NT-1 can be used in colorectal cancer research .
    NT-1
  • HY-120590
    Ruserontinib

    SKLB1028

    		 EGFR FLT3 Bcr-Abl Cancer
    Ruserontinib (SKLB1028) is an orally active multikinase inhibitor of EGFR, FLT3 and Abl, with an IC50 value of 55 nM for human FLT3, and has antitumor activity .
    Ruserontinib
  • HY-111553
    TAS0728

    		EGFR Cancer
    TAS0728 is a potent, selective, orally active, irreversible and covalent-binding HER2 inhibitor, with an IC50 of 13 nM. TAS0728 also shows IC50s of 4.9, 8.5, 31, 65, 33, 25 and 86 nM for BMX、HER4、BLK、EGFR、JAK3、SLK and LOK respectively. Furthermore, TAS0728 exhibits robust and sustained inhibition of the phosphorylation of HER2, HER3, and downstream effectors .
    TAS0728
  • HY-144760
    EGFR-IN-3

    		EGFR Apoptosis Cancer
    EGFR-IN-3 (Compound 4c) is a potent EGFR inhibitor with an IC50 of 0.32 µM against EGFRwt-TK. EGFR-IN-3 shows cytotoxic activity against cancer cell lines and induces apoptosis .
    EGFR-IN-3
  • HY-130608
    Mutated EGFR-IN-3

    		EGFR Cancer
    Mutated EGFR-IN-3 (compound 3) is a potent, ATP-competitive and highly selective allosteric dibenzodiazepinone inhibitor of the EGFR(L858R/T790M) and EGFR(L858R/T790M/C797S) mutants with IC50 values of 12 nM and 13 nM, respectively .
    Mutated EGFR-IN-3
  • HY-144605
    PROTAC EGFR degrader 3

    		EGFR PROTACs Cancer
    PROTAC EGFR degrader 3 is a potent PROTAC EGFR degrader. PROTAC EGFR degrader 3 shows excellent cellular activity against the H1975 and HCC827 cells with high selectively. PROTAC EGFR degrader 3 shows that the lysosome is involved in the degradation process of EGFR mutant degradation .
    PROTAC EGFR degrader 3
  • HY-161136
    EGFR/STAT3-IN-1

    		EGFR STAT Cancer
    EGFR/STAT3-IN-1 (Compound 5k) is a dual inhibitor of EGFR/STAT3 with IC50 values for EGFR and STAT3 are 41 and 3.34 nM, respectively. EGFR/STAT3-IN-1 has antitumor activity .
    EGFR/STAT3-IN-1
  • HY-176788
    EGFR Ligand-Linker Conjugates 1

    		Target Protein Ligand-Linker Conjugates EGFR Cancer
    EGFR Ligand-Linker Conjugates 1 is an Target Protein Ligand-Linker Conjugate that incorporates a ligand for EGFR (HY-150905) and a PROTAC linker, which recruits E3 ligases. EGFR Ligand-Linker Conjugates 1 can be used for synthesis of PROTAC EGFR degrader 3 (HY-144605) .
    EGFR Ligand-Linker Conjugates 1
  • HY-107459
    (E/Z)-AG490
    1 Publications Verification

    (E/Z)-TyrphostIN AG490; (E/Z)-TyrphostIN B42

    		 EGFR STAT JAK Cancer
    (E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is a racemic compound of (E)-AG490 and (Z)-AG490 isomers. (E)-AG490 (HY-12000) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.
    (E/Z)-AG490
  • HY-174415
    ZSH-2117

    		PROTACs EGFR Akt ERK Cancer
    ZSH-2117 is a covalent and selective EGFR PROTAC degrader with a DC50 of 45 nM in Ba/F3-EGFR L858R/T790M/C797S cells. ZSH-2117 significantly inhibits cell proliferation and reduces the downstream EGFR signaling proteins level of AKT and ERK. ZSH-2117 effectively inhibits tumor growth in Ba/F3-EGFR L858R/T790M/C797S xenograft mice model . Pink: EGFR ligand (HY-175162); Blue: NEDD4 ligase ligand (HY-175159); Black: linker
    ZSH-2117
  • HY-155227B
    ALK/EGFR-IN-3

    		Anaplastic lymphoma kinase (ALK) Cancer
    ALK/EGFR-IN-3 is a dual inhibitor of ALK and EGFR. ALK/EGFR-IN-3 inhibits the cell proliferation of H1975, PC9, and Baf3-EML4-ALK cancer cell lines with IC50s of 0.1360, 0.0332, and 0.0339 μM, respectively .
    ALK/EGFR-IN-3
  • HY-157432
    EGFR-IN-97

    		EGFR Apoptosis Cancer
    EGFR-IN-97 (compound 6q) is a EGFR inhibitor. EGFR-IN-97 shows inhibitory activity against Ba/F3-EGFR L858R/T790M/C797S and Ba/F3-EGFR Del19/T790M/C797S cells, with IC50 values of 0.42 μM and 0.41 μM, respectively. EGFR-IN-97 can promote apoptosis of NCI-H1975-EGFR L858R/T790M/C797S cells at the concentration of 0.8 μM .
    EGFR-IN-97
  • HY-170928
    DA-0157

    		EGFR Anaplastic lymphoma kinase (ALK) Cytochrome P450 Cancer
    DA-0157 is the orally active inhibitor for EGFR and ALK that overcomes drug-resistant mutations of EGFR C797S and ALK in NSCLC) cells. DA-0157 inhibits the proliferation of Ba/F3-EGFR Del19/T790M/C797S (IC50 = 6.9 nM), Ba/F3-EGFR WT (IC50 = 0.83 μM), Ba/F3-EML4-ALK-L1196M (IC50 = 5.5 nM), and Ba/F3-EML4-ALK (IC50 = 7.4 nM). DA-0157 inhibits CYP2D6 with IC50 of 5.26 μM. DA-0157 exhibits antitumor efficacy in mouse models .
    DA-0157
  • HY-173500
    MG-3C

    		MMP Apoptosis EGFR STAT Cancer
    MG-3C is a potent matrix metalloproteinase 9 (MMP-9) inhibitor. MG-3C can selectively kill non-small-cell lung cancer (NSCLC) cells harboring the EGFR T790M mutation. MG-3C blocks the EGFR/STAT3 signaling pathway, inducing G2/M phase arrest, growth inhibition, and apoptosis of cancer cells. MG-3C is promising for research of lung cancer .
    MG-3C
  • HY-161269
    EGFR-IN-101

    		EGFR Cancer
    EGFR-IN-101 (I-10) is a 2-phenylamino pyrimidine derivative. EGFR-IN-101 is a EGFR inhibitor. The IC50 values for EGFR L858R/T790M/C797S and Ba/F3-EGFR L858R/T790M/C797S are 33.26 and 106.4 nM, respectively. EGFR-IN-101 can be used IN the study of non-small cell lung cancer (NSCLC) .
    EGFR-IN-101
  • HY-107459R
    (E/Z)-AG490 (Standard)

    (E/Z)-TyrphostIN AG490 (Standard); (E/Z)-TyrphostIN B42 (Standard)

    		 Reference Standards EGFR STAT JAK Cancer
    (E/Z)-AG490 (Standard) is the analytical standard of (E/Z)-AG490 (HY-107459). This product is intended for research and analytical applications. (E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is a racemic compound of (E)-AG490 and (Z)-AG490 isomers. (E)-AG490 (HY-12000) is a tyrosine Kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.
    (E/Z)-AG490 (Standard)
  • HY-N9684
    Degalactotigonin

    		EGFR GSK-3 Hedgehog Akt ERK Apoptosis Cancer
    Degalactotigonin is a saponin-selective inhibitor targeting the EGFR, GSK3β and Hedgehog/Gli1 pathways and can be isolated from Solanum nigrum (Solanum nigrum). Degalactotigonin inhibits EGFR phosphorylation and the downstream Akt/ERK signaling pathway, and at the same time inhibits the Hedgehog/Gli1 pathway through GSK3β inactivation, thereby inducing cancer cell apoptosis, arresting the cell cycle, and inhibiting migration and invasion. Degalactotigonin can be used in targeted research on malignant tumors such as pancreatic cancer and osteosarcoma .
    Degalactotigonin
  • HY-P11757
    Cyclo[K(N3)larllt]

    		EGFR Cancer
    Cyclo[K(N3)larllt] is a seven-membered cyclic peptide targeting EGFR, with a Kd value of 5.09 μM, and exhibits binding selectivity toward homologous proteins HER2 and HER3. Cyclo[K(N3)larllt] has no cytotoxicity and shows no growth inhibitory effect on cancer cells overexpressing EGFR. Cyclo[K(N3)larllt] can serve as a ligand for EGFR-targeted fluorescent conjugates, which is applicable to the detection of cancers with EGFR overexpression. Cyclo[K(N3)larllt] can be used in the research of colorectal cancer .
    Cyclo[K(N3)larllt]
  • HY-P991977
    BSI-001

    5G9

    		 EGFR Apoptosis PARP Akt ERK Cancer
    BSI-001 (5G9) is a HER2-targeting antibody. BSI-001 inhibits cell proliferation and migration, induces apoptosis and PARP cleavage, and suppresses HER2-mediated downstream signaling pathways (including the phosphorylation of EGFR, HER3, AKT and ERK) when combined with Trastuzumab (HY-P9907) in HER2-positive cancer cells. BSI-001 exhibits synergistic anti-tumor efficacy in animal models of gastric cancer and breast cancer when combined with Trastuzumab. BSI-001 can be used for the research of HER2-positive breast cancer and HER2-overexpressing gastric cancer .
    BSI-001

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: